Neuroblastoma

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

Rapid Administration Pilot for Infusing Dinutuximab

Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation

MIBG With Dinutuximab +/- Vorinostat

Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients

ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma

Fecal Microbiota Transplant for Neuroblastoma in a Single Patient

An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

Molecular-Guided Therapy for Childhood Cancer